Position
Invesco Ltd. in Neumora Therapeutics, Inc.
Back to the book · All holders of NMRA
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $32.9K$1.79 → $1.95
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 227.6K | $407.4K | — | — | — | 0.0% |
| Q1 2026 | 205.9K | $401.6K | $1.95 | $32.9K | −$38.8K | 0.0% |